Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins

Abstract

A high sst(5) /sst(2) ratio might be predictive of a positive outcome to long-term treatment with somatostatin analogues in TSHomas. Moreover, combined somatostatin and D(2) receptor targeting might be considered as a potential tool to improve the response rate in octreotide-resistant tumours.